Can-Fite BioPharma Ltd.
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
CANF | TA
Overview
Corporate Details
- ISIN(s):
- IL0010944739 (+2 more)
- LEI:
- 549300ZLRH6GSBOHFZ59
- Country:
- Israel
- Address:
- PO BOX 7537, 4917000 PETACH-TIKVA
- Website:
- https://www.canfite.com/
- Sector:
- Manufacturing
Description
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-22 00:29 |
The Company’s Special General Meeting was adjourned due to lack of quorum, and …
|
English | HTM • 70.2 KB | ||
| 2023-02-22 00:14 |
The Company’s Special General Meeting was adjourned due to lack of quorum, and …
|
English | PDF • 102.4 KB | ||
| 2023-02-22 00:14 |
The Company’s Special General Meeting was adjourned due to lack of quorum, and …
|
English | HTM • 36.6 KB | ||
| 2023-02-14 14:59 |
FORM 6-K -Novel Approach to Treating Advanced Liver Cancer with Namodenoson Pub…
|
English | PDF • 158.2 KB | ||
| 2023-02-14 14:59 |
FORM 6-K -Novel Approach to Treating Advanced Liver Cancer with Namodenoson Pub…
|
English | HTM • 36.2 KB | ||
| 2023-02-11 02:39 |
424b3- Prospectus Supplement
|
Hebrew (modern) | PDF • 12.3 MB | ||
| 2023-02-11 02:39 |
424b3- Prospectus Supplement
|
English | HTM • 36.4 KB | ||
| 2023-02-11 02:36 |
AMENDMENT TO F-1-REGISTRATION STATEMENT
|
Hebrew (modern) | PDF • 12.9 MB | ||
| 2023-02-11 02:36 |
AMENDMENT TO F-1-REGISTRATION STATEMENT
|
English | HTM • 36.3 KB | ||
| 2023-02-01 02:01 |
FORM F-1 -Registration statement of 955,909,800 Ordinary Shares represented by …
|
English | PDF • 1.4 MB | ||
| 2023-02-01 02:01 |
FORM F-1 -Registration statement of 955,909,800 Ordinary Shares represented by …
|
English | HTM • 36.4 KB | ||
| 2023-01-24 15:14 |
Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A P…
|
English | PDF • 160.8 KB | ||
| 2023-01-24 15:14 |
Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A P…
|
English | HTM • 35.9 KB | ||
| 2023-01-14 13:30 |
Notice of extraordinary meeting that will be held on February 21, 2023, To appr…
|
English | PDF • 736.1 KB | ||
| 2023-01-14 13:30 |
Notice of extraordinary meeting that will be held on February 21, 2023, To appr…
|
English | PDF • 1.1 MB |
Automate Your Workflow. Get a real-time feed of all Can-Fite BioPharma Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Can-Fite BioPharma Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Can-Fite BioPharma Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
